VG-3927

· Vigil Neuroscience, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for VG-3927, covering 2025-02-07 to 2025-02-07. Get the full timeline:

Most recent: Clinical Trial Update: A Phase 1 Study of VG-3927 in Healthy Adults and Patients With Alzheimer's Disease [Phase 1]